U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06954467) titled 'JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma' on April 18.
Brief Summary: This open-label, multicenter phase II study was designed to evaluate the safety and efficacy of JS207 alone or in combination with JS007 as first-line treatment in subjects with advanced HCC.
The subjects were all subjects with unresectable, locally advanced, recurrent, or metastatic HCC who had not received previous systemic therapy. Planned to enroll 43 to 72 subjects.The study was divided into two stages, dose exploration stage (3-12 cases) and random expansion stage (40-60 cases).After the dose exploration phase, a...